Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

August 15, 2025

Study Completion Date

October 31, 2025

Conditions
Breast Cancer
Interventions
DRUG

WH002

"Group A(ddWH002-ddEC): Regimen for Group A during Cycles 1-Cycles 4:WH002, 260 mg/m² administered intravenously on Day 1, with a cycle length of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group A during Cycles 5-Cycles 8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with each cycle lasting 2 weeks (Q2W), continued for 4 consecutive cycles."

DRUG

paclitaxel injection

"Group B (ddP-ddEC):~Regimen for Group B during Cycles C1-C4:~• Paclitaxel Injection (Paclitaxel®) 175 mg/m², administered intravenously on Day 1, with a cycle duration of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group B during Cycles C5-C8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with cycles recurring every 2 weeks (Q2W), for a series of 4 cycles."

Trial Locations (1)

100021

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing

All Listed Sponsors
collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

Beijing Wehand-Bio Pharmaceutical Co., Ltd

INDUSTRY

NCT06513364 - Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer | Biotech Hunter | Biotech Hunter